Abizer Gaslightwala

CIK: 0002049375

Transaction Breakdown

Open Market Buys (P)11 (39.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (7.1%)

Derivative conversions

Awards (A)15 (53.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AKTX

Akari Therapeutics Plc

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (28 total)

AKTX
Akari Therapeutics Plc
Oct 14, 2026
Exercise(M)
Direct
19.3K shares at avg. $0.00$7.733
AKTX
Akari Therapeutics Plc
Oct 14, 2026
Exercise(M)
Direct
7.7K shares at avg. $0.00$3.093
AKTX
Akari Therapeutics Plc
Sep 29, 2026
Award(A)
Direct
6.4K shares at avg. $9.72$62K
AKTX
Akari Therapeutics Plc
Aug 18, 2026
Award(A)
Stock Option (Right to Buy)
Direct
174K shares-
AKTX
Akari Therapeutics Plc
Jun 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
15.6K shares-
AKTX
Akari Therapeutics Plc
Jun 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
5.5K shares-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Warrants to purchase American Depositary Shares ("ADRs")
Direct
309.3K shares-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Pre-Funded Warrants to purchase ADRs
Direct
773.3K shares at avg. $0.40-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Warrants to purchase ADRs
Direct
773.3K shares-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Pre-Funded Warrants to purchase ADRs
Direct
309.3K shares at avg. $0.40-
AKTX
Akari Therapeutics Plc
Aug 25, 2025
Purchase(P)
Direct
3K shares at avg. $0.90$3K
AKTX
Akari Therapeutics Plc
Aug 22, 2025
Purchase(P)
Direct
8K shares at avg. $0.93$7K
AKTX
Akari Therapeutics Plc
Aug 21, 2025
Purchase(P)
Direct
10K shares at avg. $0.94$9K
AKTX
Akari Therapeutics Plc
Jun 24, 2025
Purchase(P)
Direct
5.2K shares at avg. $1.16$6K
AKTX
Akari Therapeutics Plc
Jun 23, 2025
Purchase(P)
Direct
943 shares at avg. $1.15$1K
AKTX
Akari Therapeutics Plc
Jun 20, 2025
Purchase(P)
Direct
10K shares at avg. $1.20$12K
AKTX
Akari Therapeutics Plc
Jun 17, 2025
Purchase(P)
Direct
15K shares at avg. $1.20$18K
AKTX
Akari Therapeutics Plc
Jun 13, 2025
Award(A)
Direct
25K shares at avg. $1.19$30K
AKTX
Akari Therapeutics Plc
Jun 12, 2025
Award(A)
Direct
20K shares at avg. $1.23$25K
AKTX
Akari Therapeutics Plc
Jun 10, 2025
Award(A)
Direct
20K shares at avg. $1.27$25K
AKTX
Akari Therapeutics Plc
Mar 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
600K shares-
AKTX
Akari Therapeutics Plc
Mar 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
1.1M shares-
AKTX
Akari Therapeutics Plc
Mar 6, 2025
Award(A)
Direct
133.9K shares at avg. $1.12$150K
AKTX
Akari Therapeutics Plc
Jan 10, 2025
Award(A)
Direct
11.6K shares at avg. $1.22$14K
AKTX
Akari Therapeutics Plc
Jan 10, 2025
Award(A)
Direct
11.4K shares at avg. $1.22$14K

		Type	Shares	Price		Ownership
Oct 14, 2026	AKTX Akari Therapeutics Plc	Exercise(M)	19,333	$0.00	$8	Direct
Oct 14, 2026	AKTX Akari Therapeutics Plc	Exercise(M)	7,733	$0.00	$3	Direct
Sep 29, 2026	AKTX Akari Therapeutics Plc	Award(A)	6,430	$9.72	$62,500	Direct
Aug 18, 2026	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	174,000	-	-	Direct
Jun 24, 2026	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	15,563	-	-	Direct
Jun 24, 2026	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	5,500	-	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Warrants to purchase American Depositary Shares ("ADRs")	309,328	-	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Pre-Funded Warrants to purchase ADRs	773,323	$0.40	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Warrants to purchase ADRs	773,323	-	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Pre-Funded Warrants to purchase ADRs	309,328	$0.40	-	Direct
Aug 25, 2025	AKTX Akari Therapeutics Plc	Purchase(P)	3,000	$0.90	$2,700	Direct
Aug 22, 2025	AKTX Akari Therapeutics Plc	Purchase(P)	8,000	$0.93	$7,440	Direct
Aug 21, 2025	AKTX Akari Therapeutics Plc	Purchase(P)	10,000	$0.94	$9,400	Direct
Jun 24, 2025	AKTX Akari Therapeutics Plc	Purchase(P)	5,203	$1.16	$6,035	Direct
Jun 23, 2025	AKTX Akari Therapeutics Plc	Purchase(P)	943	$1.15	$1,084	Direct
Jun 20, 2025	AKTX Akari Therapeutics Plc	Purchase(P)	10,000	$1.20	$12,000	Direct
Jun 17, 2025	AKTX Akari Therapeutics Plc	Purchase(P)	15,000	$1.20	$18,000	Direct
Jun 13, 2025	AKTX Akari Therapeutics Plc	Award(A)	25,000	$1.19	$29,750	Direct
Jun 12, 2025	AKTX Akari Therapeutics Plc	Award(A)	20,000	$1.23	$24,600	Direct
Jun 10, 2025	AKTX Akari Therapeutics Plc	Award(A)	20,000	$1.27	$25,400	Direct
Mar 20, 2025	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	600,000	-	-	Direct
Mar 20, 2025	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	1,100,000	-	-	Direct
Mar 6, 2025	AKTX Akari Therapeutics Plc	Award(A)	133,928	$1.12	$149,999	Direct
Jan 10, 2025	AKTX Akari Therapeutics Plc	Award(A)	11,640	$1.22	$14,201	Direct
Jan 10, 2025	AKTX Akari Therapeutics Plc	Award(A)	11,439	$1.22	$13,956	Direct

1-25 of 28 transactions

About Gaslightwala Abizer

Gaslightwala Abizer (SEC CIK 0002049375) files insider reports with the SEC as CEO of Akari Therapeutics Plc (AKTX).

Signal8 holds 18 ownership filings by Gaslightwala Abizer (1 Form 3, 17 Form 4), filed between Dec 26, 2024 and Oct 16, 2026. Those filings report 28 transactions, from Dec 26, 2024 to Oct 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Gaslightwala Abizer's filings is in TAMPA, FL.

Recent filings by Gaslightwala Abizer

Oct 14, 2026: Option exercises of AKTX shares (2 lines, Form 4, code M).
Sep 29, 2026: Grant or award of AKTX shares (Form 4, code A).
Aug 18, 2026: Grant or award of AKTX derivative securities (Form 4, code A).
Jun 24, 2026: Grants or awards of AKTX derivative securities (2 lines, Form 4, code A).
Dec 16, 2025: Open-market purchases of AKTX derivative securities (4 lines, Form 4, code P).

Other insiders filing for Akari Therapeutics Plc (AKTX)

Prudo-Chlebosz Raymond, Director
Huh Hoyoung, Director
Patel Sandip I, Director
Bazemore Robert B, Director
Patel Samir Rashmikant, Director
Vat-Ho Vatnak, Chief Business Officer

How to read Form 4 transaction codes